NOVAVAX INC Accumulated Other Comprehensive Income
NOVAVAX INC (NVAX) had Accumulated Other Comprehensive Income of -$7.45 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$7.45M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$5.07M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $2.01M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.75M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$7.45M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$5.07M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.01M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$1.75M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$458.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.61M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$22.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.60M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$10.51M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$10.82M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $2.72M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$11.86M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$8.18M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$3.17M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$6.38M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$23.79M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$10.87M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$1.31M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$1.35M 10-K · filed 2023-02-28 |
| 2021-09-30 | $861.00K 10-Q · filed 2021-11-05 |
| 2021-06-30 | $4.17M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$357.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $7.02M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$5.00M 10-Q · filed 2020-11-10 |
| 2020-06-30 | -$13.20M 10-Q · filed 2020-08-10 |
| 2020-03-31 | -$14.49M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$12.51M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$13.85M 10-Q · filed 2019-11-07 |
| 2019-06-30 | -$12.29M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$12.36M 10-Q · filed 2019-05-02 |
| 2018-12-31 | -$11.19M 10-K · filed 2020-03-11 |
| 2018-09-30 | -$11.03M 10-Q · filed 2018-11-07 |
| 2018-06-30 | -$11.17M 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$9.07M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$8.62M 10-K · filed 2019-03-18 |
| 2017-09-30 | -$8.30M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$9.60M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$11.34M 10-Q · filed 2017-05-08 |
| 2016-12-31 | -$11.81M 10-K · filed 2018-03-14 |
| 2016-09-30 | -$9.80M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$9.14M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$7.55M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$9.12M 10-K · filed 2017-02-27 |
| 2015-09-30 | -$9.07M 10-Q · filed 2015-11-09 |
| 2015-06-30 | -$8.71M 10-Q · filed 2015-08-10 |
| 2015-03-31 | -$9.76M 10-Q · filed 2015-05-07 |
| 2014-12-31 | -$6.61M 10-K · filed 2016-02-29 |
| 2014-09-30 | -$4.11M 10-Q · filed 2014-11-06 |
| 2014-06-30 | -$1.29M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $90.00K 10-Q · filed 2014-05-08 |
| 2013-12-31 | $839.00K 10-K · filed 2015-02-27 |
| 2013-09-30 | $1.11M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $637.00K 10-Q · filed 2013-08-08 |
| 2013-03-31 | $469.00K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $430.00K 10-K · filed 2014-03-12 |
| 2012-09-30 | $1.04M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $940.00K 10-Q · filed 2012-08-09 |
| 2012-03-31 | $976.00K 10-Q · filed 2012-05-09 |
| 2011-12-31 | $832.00K 10-K · filed 2013-03-12 |
| 2011-09-30 | $913.00K 10-Q · filed 2011-11-08 |
| 2011-06-30 | $910.00K 10-Q · filed 2011-08-09 |
| 2010-12-31 | $772.00K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |